Anteris Technologies Global Corp. (AVR) SEC Filings & Earnings Calls

Short-term extension may indicate ongoing negotiations for a replacement agreement; no material risk identified.

“Term expires on earlier of December 31, 2026 or execution of a separate supply and quality agreement intended to replace the Agreement.”

Potential dilution from equity grants if approved.

“Contingent option and PSU grants totaling over 2.9 million shares.”

Pre-commercial stage with no approved product revenue, high cash burn

“Loss from ordinary activities after tax ($51,675k) on revenue of $1,503k”

Clinical and regulatory risk for DurAVR THV approval

“statements regarding the PARADIGM Trial, CMS reimbursement eligibility, clinical development timelines and potential commercialization” · word for word

Dependence on successful commercialization and market adoption

“Anteris is a science-driven company... delivering restorative solutions to structural heart disease patients”

No approved product; history of losses

“As a development-stage company, we have incurred losses since our inception. We anticipate that we will continue to incur losses for the foreseeable future and there can be no assurance that we will ever achieve or maintain profitability.” · word for word

Clinical and regulatory uncertainty

“We intend to establish the safety and effectiveness of the DurAVR ® THV in patients with severe aortic stenosis in our global pivotal study (the “PARADIGM Trial”).” · word for word

Need for additional capital

“We anticipate that we will require additional funds in order to achieve our long-term goals including completing the R&D of our current products.” · word for word

Dependence on single product

“Our lead product, the DurAVR ® Transcatheter Heart Valve (“THV”) System, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis.” · word for word

Regulatory compliance risk from administrative oversight; resolved.

“Late lodgement of cleansing notice under Corporations Act; court order obtained.”

Regulatory compliance risk from late cleansing notice; being resolved.

“Late lodgement of cleansing notice; company intends to apply for court relief.”

Potential dilution from ATM offering; no immediate sales guaranteed.

“The Company cannot provide any assurances that it will issue any Common Stock pursuant to the Agreement.” · word for word

High cash burn rate for clinical trial; reliance on capital raises for funding.

“Net operating cash outflows of $28.7M for Q1 2026; capital raises of $320M to support PARADIGM Trial.”

Pre-revenue development stage; no approved product

“We anticipate that we will continue to incur losses for the foreseeable future and there can be no assurance that we will ever achieve or maintain profitability.” · word for word

Dependence on PARADIGM Trial success for FDA PMA

“It is anticipated that the design of the PARADIGM Trial will provide the primary clinical evidence on which the FDA could base a decision for Premarket Approval (PMA).” · word for word

Future capital needs uncertain

“We anticipate that we will require additional funds in order to achieve our long-term goals including completing the R&D of our current products.” · word for word

Lease obligation increases fixed cost base; potential cash flow strain if revenue growth lags.

“Long-term lease with annual escalations and operating expense pass-throughs.”

Equity dilution from supplemental grant, though small relative to total shares

“Supplemental RSU grant of $500,000 value”

Cash burn risk: all IPO proceeds fully used, negative tangible net worth, and widening losses.

“IPO proceeds of $80M fully used; net tangible assets per share negative; loss increased 24%.”

Pre-revenue stage risk: revenue decline and heavy R&D spending on DurAVR THV pivotal trial.

“$59.5M used for DurAVR THV development and pivotal trial; revenue only $1.9M.”

Pre-revenue clinical-stage company with no guarantee of commercial success

“We are a development stage company and have incurred net losses each year since operation, however, we believe that we have significant growth potential in a large, underpenetrated and growing TAVR market.” · word for word

Medtronic influence and potential conflict of interest

“Medtronic is in a position to exercise influence over matters affecting our stockholders or requiring stockholder approval, including the election of the Board, amendments to our governing documents and the determination of significant corporate actions.” · word for word

Dependence on successful clinical trial outcomes and regulatory approvals

“We do not expect to generate significant revenue until we obtain regulatory approval to market and sell our products and sales of our products have commenced.” · word for word

Need for substantial additional capital

“We anticipate that we will require substantial additional funds in order to achieve our long-term goals and complete the R&D of our current products.” · word for word

Dilution from unregistered share issuance; reliance on successful clinical and regulatory outcomes for value creation.

“Unregistered shares issued to Medtronic; company has accumulated deficit and no current revenue from DurAVR THV.”

Dependence on successful PARADIGM trial outcomes and regulatory approval for DurAVR THV; clinical and regulatory risks remain.

“PARADIGM Trial is a prospective randomized controlled trial evaluating DurAVR THV vs commercially available TAVRs; regulatory approval not yet obtained.” · word for word

Loss of supply agreement revenue stream, though company states no material impact

“The termination of this contract does not materially impact on the financial results of the Company.” · word for word

Clinical trial risk remains; PARADIGM trial enrollment and outcomes are pending.

“This pooled analysis of 100 patients represents approximately 20% of the planned DurAVR enrolment for the all-comers randomized cohort of PARADIGM.” · word for word

Cash burn rate high relative to cash balance

“Cash $9.1M vs operating cash outflow $59.3M for 9 months; may require financing.”

Going concern risk due to insufficient cash runway

“We do not believe that our current cash on hand would fund our cash needs for the 12 months following September 30, 2025. Even with the proceeds from the Private Placement, we will need additional capital to fund our operations.” · word for word

Clinical trial execution risk

“The PARADIGM Trial is a prospective, randomized, controlled multicenter, international study... It is anticipated that the design of the PARADIGM Trial will provide the primary clinical evidence on which the FDA could base a decision for the Premarket Approval.” · word for word

No recurring revenue from core product

“We do not expect to generate significant revenue until we obtain regulatory approval to market and sell our products and sales of our products have commenced.” · word for word

Clinical trial risk: PARADIGM trial may fail to meet endpoints

“Trial assesses non-inferiority on composite endpoint; failure would delay or prevent PMA approval”

Regulatory approval risk: PMA submission requires high level of clinical evidence

“PMA application requires high level of clinical evidence to demonstrate reasonable assurance of safety and effectiveness”

Clinical trial risk: PARADIGM trial may fail to meet endpoints or face enrollment delays.

“Trial is pivotal for PMA; any failure could delay or prevent commercialization.”

Dilution risk from unregistered equity issuance; terms not disclosed in excerpt.

“Unregistered sales of equity securities.” · word for word

Dilution from equity offering.

“Issuance of 2,244,896 shares and 2,788,064 CDIs with warrants.”